Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of the raw material drug Agomelatine [1] Group 1 - Agomelatine primarily acts by stimulating melatonin receptors MT1 and MT2 and antagonizing 5-HT2C, helping to restore disrupted biological rhythms and exerting antidepressant effects [1] - The formulation of Agomelatine is mainly used clinically for the treatment of adult depression [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient Agomelatine, which is primarily used for treating adult depression [1] Group 1: Company Information - The company involved is Guoyao Modern (国药现代), with its wholly-owned subsidiary Jiangsu Weichida Pharmaceutical Co., Ltd. (国药江苏威奇达) receiving the approval [1] - Agomelatine acts on melatonin receptors MT1 and MT2 and antagonizes 5-HT2C, helping to restore disrupted biological rhythms and exerting antidepressant effects [1] Group 2: Product Information - The clinical application of Agomelatine is mainly for the treatment of adult depression [1]